Bio Plus Co., Ltd
Financials
Valuation Metrics
Bio Plus Co., Ltd's Market Cap is ₩2241B. At end of 2025 it was ₩3101B. Ranked #759 of 2,436 in KR market (top 31%), #332 of 1,649 on KOSDAQ (top 20%), #26 of 96 in Health Care Equipment & Services (top 27%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 224.06B KRW | KR#759/2,436 Sec#26/96 |
| Revenue | 94.42B KRW | KR#1,423/2,436 Sec#37/96 |
| Net Income | 19.47B KRW | KR#658/2,436 Sec#16/96 |
| Total Assets | 297.50B KRW | KR#1,024/2,436 Sec#22/96 |
| Net Assets | 199.02B KRW | KR#928/2,436 Sec#23/96 |
| Employees | 155 | KR#1,290/2,436 Sec#42/96 |
| Value | ||
| P/E | 11.51x | KR#793/2,436 Sec#23/96 |
| P/B | 1.13x | KR#1,584/2,436 Sec#46/96 |
| P/S | 2.37x | KR#1,909/2,436 Sec#56/96 |
| EV/EBITDA | 20.70x | KR#1,034/2,436 Sec#32/96 |
| FCF Yield | -14.21% | KR—/2,436 Sec—/96 |
| Profitability | ||
| ROE | 9.78% | KR#528/2,436 Sec#25/96 |
| ROA | 6.55% | KR#471/2,436 Sec#24/96 |
| Op. Margin | 14.36% | KR#296/2,436 Sec#24/96 |
| Revenue Growth | 15.35% | KR#743/2,436 Sec#33/96 |
| Earnings Growth | -6.14% | KR#952/2,436 Sec#36/96 |
| Financial Health | ||
| Debt Ratio | 149.48% | KR#1,176/2,436 Sec#61/96 |
| Total Debt | 79.60B KRW | KR#803/2,436 Sec#17/96 |
| FCF | -31.84B KRW | KR#2,012/2,436 Sec#78/96 |
| Cash | 23.02B KRW | KR#1,155/2,436 Sec#29/96 |
| Current Ratio | 0.94x | KR#1,891/2,436 Sec#83/96 |
| Net Debt/EBITDA | 4.17x | KR#1,035/2,436 Sec#41/96 |
| Dividend | ||
| Div. Yield | 1.99% | KR#899/2,436 Sec#21/96 |
| Div. Growth | 40.00% | KR#276/2,436 Sec#13/96 |
| Performance | ||
| 1Y Return | -48.51% | KR#2,047/2,436 Sec#74/96 |
| 1M Return | -11.88% | KR#1,870/2,436 Sec#72/96 |
| From 52W High | -53.40% | KR#1,360/2,436 Sec#54/96 |
| 1Y MDD | -57.78% | KR#1,296/2,436 Sec#46/96 |
| Trading | ||
| Volume | 269,270 shares | KR#441/2,436 Sec#17/96 |
| Foreign Own. | 3.79% | KR#911/2,436 Sec#34/96 |
| Per Share | ||
| EPS | 228 KRW | KR#1,170/2,436 Sec#38/96 |
| BPS | 2,885 KRW | KR#1,838/2,436 Sec#55/96 |
Company Info
Established in 2003 and rebranded in 2013, the company expanded its business in 2025 by establishing BioPlus USA Inc. and acquiring equity. It primarily focuses on the research, development, manufacturing, and sales of hyaluronic acid-based medical devices and Bio Cosmetic products, while also concentrating on developing next-generation botulinum toxin and obesity treatments. Employing a technology-driven strategy, the company exports to over 70 overseas countries and is accelerating its global market entry by establishing an overseas subsidiary and local production facilities in China. BioPlus was established in 2003 and is headquartered in Gyeonggi-do, Seongnam-si.